Live Feeds
Press Releases
Insider Trading
FDA Approvals
Analyst Ratings
Insider Trading
SEC filings
Market insights
Analyst Ratings
Alerts
Subscriptions
Settings
RSS Feeds
Live Feeds
Press Releases
Insider Trading
FDA Approvals
Analyst Ratings
Insider Trading
SEC filings
Market insights
Analyst Ratings
Alerts
Subscriptions
Settings
RSS Feeds
Publish
Dashboard
Subscribe to $SNTI
Senti Biosciences Inc.
Subscribe to $SNTI
$SNTI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
IPO Year: 2021
Exchange: NASDAQ
Recent Analyst Ratings for Senti Biosciences Inc.
Date
Price Target
Rating
Analyst
6/6/2025
$5.00
Buy
Laidlaw
10/7/2022
$7.50
Equal-Weight
Morgan Stanley
See more ratings
